Ishares III Plc (IEXA) Quote

Exploring Top NASDAQ Stocks Under $1 Gaining Traction: KITT, AEMD, VTAK, TELL, KWE


https://thestreetreports.com/exploring-top-nasdaq-stocks-under-1-gaining-traction-kitt-aemd-vtak-tell-kwe/

The NASDAQ, one of the world’s largest stock exchanges, witnesses billio

Yup. The disciples and their streaking fantasies would have poor green retail believe that after all these years there's just not even one financier out there interested in setting up naked shorts for a quick buck.

great post revisited:


Talon38

Re: None

Wednesday, June 12, 2024 5:10:42 PM

Post#
461009
of 461047
Institutional holding continues to rise with State Street, BlackRock and Vanguard leading close to the 40% lev

NXU...................DUO........................https://stockcharts.com/h-sc/ui?s=DUO&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=NXU&p=D&yr=0&mn=2&dy=12&id=p84071410134

And tires wearing out fast is only because how quickly it can accelerate. Tesla introduced “chill” mode to assist with this. I actually prefer that now. Rides like butter

$80k target TODAY ✔️🚀🚀🚀💪💥💨💬

NXU..................MULN.................................https://stockcharts.com/h-sc/ui?s=NXU&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134

Get educated.

2018 model 3 with 170,000km. Bought it new. Battery still holds over 90%.

Para, why did DrJ use a non-PCAOB auditor? He can't file a form 10 till he does, apparently, per discussion on X.com.

Mr garbage don’t worry it’s coming

The key item to understand at MGON is this new management brought the company from the dead back in late 2020 after custodianship took possession in 2018 and that custodianship group failed to bring company current.
New managed did and with 3 years of past audits, Form 1A/A filed and moving

Nice gap on 60 but will it bounce off of ma9 and keep going

You remembered! Thank you, rr.
You just made my day.

Elite has completed EVERYTHING the FDA requested as of August 17, 2023 when they filed for Generic OxyContin.

If the FDA didn't request anything else during the past 10 months, we should expect the following next week:

Tentative Approval
"If a generic drug prod

The last thing a sentient being should conclude is that this company is on the up and up. Having a partnership with a company that has 3 employees and no pipeline operators and a terrible website is laughable.

European cooperation between medicine regulators and HTA bodies will be governed by the Regulation on Health Technology Assessment (EU) 2021/2282 when it becomes applicable in January 2025. The Regulation entered into force in January 2022.

https://www.ema.europa.eu/en/partners-networ

NCI......BRTX.....https://stockcharts.com/h-sc/ui?s=NCI&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=BRTX&p=D&yr=0&mn=2&dy=12&id=p84071410134

LOL. Shorting is one of the few market actions that helps keep executives honest. Otherwise there'd be practically no incentive to sniff out the bad actors.

>>I'm also in favor of doing away with short selling.

BRTX - 1.57/1.58 Up from 1.35

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

$RJDG - #Healthcare #Green #Technology #Enviromentals
RJD Green, Inc., is a publicly traded company under ticker symbol (OTC: RJDG)
The RJDG focus is economically advantageous acquisitions within emerging growth entities or companies in need of restructure, where immediate growth and

$RJDG - #Healthcare #Green #Technology #Enviromentals
RJD Green, Inc., is a publicly traded company under ticker symbol (OTC: RJDG)
The RJDG focus is economically advantageous acquisitions within emerging growth entities or companies in need of restructure, where immediate growth and

Unfortunately, the talk is cheap. What we all need to see is follow through. Great marketing program, possible purchase or merger, and positive earnings.

$$$$ Today is the Day $$$$

$$$$ $frx $$$$

Yes💯💯💯

DUO.....AMED......https://stockcharts.com/h-sc/ui?s=DUO&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=AMED&p=D&yr=0&mn=2&dy=12&id=p84071410134

LGVN - 2.48/2.49 Up from 1.81

Watching Longeveron; Zacks Small-Cap Research Issues $15.10 Price Valuation; Says Longeveron Is Focusing On Using Its Primary Treatment, Lomecel-B, To Fight A Rare Pediatric Heart Birth Defect That Devastates Families; Announced The Completion Of An Encou